Form 8-K - Current report:
SEC Accession No. 0000950170-25-021365
Filing Date
2025-02-14
Accepted
2025-02-14 16:49:20
Documents
11
Period of Report
2025-02-14
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K itrm-20250214.htm   iXBRL 8-K 40359
  Complete submission text file 0000950170-25-021365.txt   154990

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT itrm-20250214.xsd EX-101.SCH 25787
13 EXTRACTED XBRL INSTANCE DOCUMENT itrm-20250214_htm.xml XML 4709
Mailing Address 3 DUBLIN LANDINGS NORTH WALL QUAY DUBLIN 1 L2 D01 H104
Business Address 3 DUBLIN LANDINGS NORTH WALL QUAY DUBLIN 1 L2 D01 H104 (872) 225-6077
Iterum Therapeutics plc (Filer) CIK: 0001659323 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38503 | Film No.: 25630269
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)